Welcome to our dedicated page for TC BioPharm (Holdings) news (Ticker: TCBP), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) stock.
TC BioPharm (TCBP) is a clinical-stage biopharmaceutical company pioneering allogeneic gamma delta T cell therapies for oncology and infectious diseases. This page serves as the definitive source for official news, clinical trial updates, and strategic developments from the company.
Investors and industry professionals will find timely updates on regulatory milestones, financial results, and research collaborations. Our curated collection includes press releases covering clinical progress, manufacturing advancements, and partnership announcements, providing a comprehensive view of TCBP's trajectory.
Key content areas include updates on acute myeloid leukemia trials, innovations in cryopreservation technology, and expansions into new therapeutic areas. Bookmark this page to stay informed about TC BioPharm's groundbreaking work in cellular immunotherapy and its position within the competitive biopharma landscape.
TC BioPharm (NASDAQ: TCBP) has outlined its 2023 strategic plan, focusing on the development of its lead product, TCB-008, an allogeneic gamma-delta T cell therapy for cancer. The Company aims to pursue exclusive partnerships for clinical research, enhancing its competitive edge in the evolving cell therapy landscape. TCB-008 is set for FDA IND filing in Q3 2023 for Acute Myeloid Leukemia and will expand into CAR therapy targeting ovarian cancer. With over 313,000 new ovarian cancer cases reported in 2020, the Company is aligning its assets for better market positioning. TCBP is focused on establishing collaborations and increasing its intellectual property portfolio, aiming for a pivotal role in gamma-delta T cell therapies. The CEO emphasized the importance of partnerships and efficient capital management for long-term growth.
TC BioPharm (NASDAQ: TCBP), a clinical-stage biotechnology company, is set to participate in the Sequire Investor Summit from April 24-26, 2023, in San Juan, Puerto Rico. This summit offers unique tax advantages for attendees, aimed at enhancing their investment strategies. Keynote panels and training sessions will be led by industry experts, covering the latest trends and best practices.
On April 26, at 11:00 am ET, TC BioPharm management will present on Track 2. The company's focus is on developing gamma-delta T cell therapies for cancer treatment, with ongoing clinical trials targeting acute myeloid leukemia. TC BioPharm is recognized for its allogeneic approach and maintains a robust patent portfolio in this innovative field.
The report titled "Global CD276 Antibody Clinical Trials & Market Sales Forecast 2028" highlights the emerging potential of CD276 immune checkpoint inhibitors in cancer treatment. It forecasts a market value exceeding
FAQ
What is the current stock price of TC BioPharm (Holdings) (TCBP)?
What is the market cap of TC BioPharm (Holdings) (TCBP)?
